Fig. 6: Development of mNG Δ3678 virus for high-throughput neutralization and antiviral testing.
From: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
a Genome structure of mNG Δ3678 SARS-CoV-2. The mNG gene was inserted between M and N genes. b mNG foci of A549-ACE2 cells that were infected with mNG Δ3678 SARS-CoV-2 in the presence and absence of 10 µM inhibitor (remdesivir) for 24 h. Scale bar, 100 µm. c Representative FFRNT neutralization curves for a COVID-19 antibody-positive and -negative serum. d Correlation between FFRNT50 with PRNT50 values of 20 COVID-19 convalescent sera. The Pearson correlation (two-sided) efficiency and P value are shown. e Scatter-plot of FFRNT50/PRNT50 ratios. The geometric mean is shown. The error bar indicates the 95% confidence interval of the geometric mean. f Antiviral response curve of remdesivir against mNG Δ3678 SARS-CoV-2. The calculated 50% effective concentration (EC50) is indicated. g The Dose response curve of a monoclonal antibody IgG14. A549-hACE2 cells were infected with mNG Δ3678 virus in the presence of different concentrations of IgG14. The mNG signals at 24 h post-infection were used to calculate the NT50. f, g Error bars indicate the mean ± standard deviations from four technical replicates. c–g Source Data are provided as a Source Data file.
